-
1
-
-
84930899257
-
-
National Institute of Neurological Disorders and Stroke, National Insitutes of HealthNational Insitutes of Health, (accessed April 15, 2013).
-
Amyotrophic lateral sclerosis (ALS) fact sheet National Institute of Neurological Disorders and Stroke, National Insitutes of HealthNational Insitutes of Health, (accessed April 15, 2013). http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_ALS.htm.
-
Amyotrophic lateral sclerosis (ALS) fact sheet
-
-
-
3
-
-
33645867989
-
Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies
-
Bruijn LI, Cudkowicz M Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies. Expert Rev Neurother 2006, 6:417-428.
-
(2006)
Expert Rev Neurother
, vol.6
, pp. 417-428
-
-
Bruijn, L.I.1
Cudkowicz, M.2
-
4
-
-
38348998584
-
Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications
-
Cozzolino M, Ferri A, Carri MT Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid Redox Signal 2008, 10:405-443.
-
(2008)
Antioxid Redox Signal
, vol.10
, pp. 405-443
-
-
Cozzolino, M.1
Ferri, A.2
Carri, M.T.3
-
5
-
-
84856905668
-
Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis
-
Morren JA, Galvez-Jimenez N Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. Expert Opin Investig Drugs 2012, 21:297-320.
-
(2012)
Expert Opin Investig Drugs
, vol.21
, pp. 297-320
-
-
Morren, J.A.1
Galvez-Jimenez, N.2
-
6
-
-
0028097839
-
A controlled trial of riluzole in amyotrophic lateral sclerosis
-
ALS/Riluzole Study Group
-
Bensimon G, Lacomblez L, Meininger V A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994, 330:585-591. ALS/Riluzole Study Group.
-
(1994)
N Engl J Med
, vol.330
, pp. 585-591
-
-
Bensimon, G.1
Lacomblez, L.2
Meininger, V.3
-
7
-
-
0029977337
-
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
-
Amyotrophic Lateral Sclerosis/Riluzole Study Group II
-
Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996, 347:1425-1431. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
-
(1996)
Lancet
, vol.347
, pp. 1425-1431
-
-
Lacomblez, L.1
Bensimon, G.2
Leigh, P.N.3
Guillet, P.4
Meininger, V.5
-
8
-
-
84861941975
-
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
-
CD001447.
-
Miller RG, Mitchell JD, Moore DH Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012, 3. CD001447.
-
(2012)
Cochrane Database Syst Rev
, vol.3
-
-
Miller, R.G.1
Mitchell, J.D.2
Moore, D.H.3
-
9
-
-
0019845220
-
The ultrastructure of intramuscular nerves in amyotrophic lateral sclerosis
-
Atsumi T The ultrastructure of intramuscular nerves in amyotrophic lateral sclerosis. Acta Neuropathol 1981, 55:193-198.
-
(1981)
Acta Neuropathol
, vol.55
, pp. 193-198
-
-
Atsumi, T.1
-
10
-
-
0029812897
-
Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis
-
Sasaki S, Iwata M Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 1996, 47:535-540.
-
(1996)
Neurology
, vol.47
, pp. 535-540
-
-
Sasaki, S.1
Iwata, M.2
-
11
-
-
0030026832
-
Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis
-
Siklós L, Engelhardt J, Harati Y, Smith RG, Joó F, Appel SH Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 1996, 39:203-216.
-
(1996)
Ann Neurol
, vol.39
, pp. 203-216
-
-
Siklós, L.1
Engelhardt, J.2
Harati, Y.3
Smith, R.G.4
Joó, F.5
Appel, S.H.6
-
12
-
-
33750347347
-
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases
-
Lin MT, Beal MF Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
-
(2006)
Nature
, vol.443
, pp. 787-795
-
-
Lin, M.T.1
Beal, M.F.2
-
13
-
-
71549121668
-
The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start?
-
Lee J, Boo JH, Ryu H The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start?. Adv Drug Deliv Rev 2009, 61:1316-1323.
-
(2009)
Adv Drug Deliv Rev
, vol.61
, pp. 1316-1323
-
-
Lee, J.1
Boo, J.H.2
Ryu, H.3
-
14
-
-
71849088759
-
Mitochondria: a therapeutic target in neurodegeneration
-
Moreira PI, Zhu X, Wang X, et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 2010, 1802:212-220.
-
(2010)
Biochim Biophys Acta
, vol.1802
, pp. 212-220
-
-
Moreira, P.I.1
Zhu, X.2
Wang, X.3
-
15
-
-
79952758621
-
Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis
-
Cheah BC, Kiernan MC Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010, 13:911-920.
-
(2010)
IDrugs
, vol.13
, pp. 911-920
-
-
Cheah, B.C.1
Kiernan, M.C.2
-
16
-
-
84862793575
-
Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency
-
Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res 2012, 1446:1-11.
-
(2012)
Brain Res
, vol.1446
, pp. 1-11
-
-
Alavian, K.N.1
Dworetzky, S.I.2
Bonanni, L.3
-
17
-
-
29244439896
-
Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]
-
Danzeisen R, Schwalenstoecker B, Gillardon F, et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 2006, 316:189-199.
-
(2006)
J Pharmacol Exp Ther
, vol.316
, pp. 189-199
-
-
Danzeisen, R.1
Schwalenstoecker, B.2
Gillardon, F.3
-
18
-
-
84856101199
-
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
-
Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011, 17:1652-1656.
-
(2011)
Nat Med
, vol.17
, pp. 1652-1656
-
-
Cudkowicz, M.1
Bozik, M.E.2
Ingersoll, E.W.3
-
19
-
-
84875744026
-
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials
-
Berry JD, Miller R, Moore DH, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14:162-168.
-
(2013)
Amyotroph Lateral Scler Frontotemporal Degener
, vol.14
, pp. 162-168
-
-
Berry, J.D.1
Miller, R.2
Moore, D.H.3
-
20
-
-
0033564460
-
Combining mortality and longitudinal measures in clinical trials
-
Finkelstein DM, Schoenfeld DA Combining mortality and longitudinal measures in clinical trials. Stat Med 1999, 18:1341-1354.
-
(1999)
Stat Med
, vol.18
, pp. 1341-1354
-
-
Finkelstein, D.M.1
Schoenfeld, D.A.2
-
21
-
-
0034574407
-
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
-
World Federation of Neurology Research Group on Motor Neuron Diseases
-
Brooks BR, Miller RG, Swash M, Munsat TL El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, 1:293-299. World Federation of Neurology Research Group on Motor Neuron Diseases.
-
(2000)
Amyotroph Lateral Scler Other Motor Neuron Disord
, vol.1
, pp. 293-299
-
-
Brooks, B.R.1
Miller, R.G.2
Swash, M.3
Munsat, T.L.4
-
22
-
-
78651262763
-
Usefulness of the ALSAQ-5 scale in evaluation of quality of life in amyotrophic lateral sclerosis
-
Gołab-Janowska M, Honczarenko K, Stankiewicz J Usefulness of the ALSAQ-5 scale in evaluation of quality of life in amyotrophic lateral sclerosis. Neurol Neurochir Pol 2010, 44:560-566.
-
(2010)
Neurol Neurochir Pol
, vol.44
, pp. 560-566
-
-
Gołab-Janowska, M.1
Honczarenko, K.2
Stankiewicz, J.3
-
23
-
-
36148960127
-
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
-
for the Western ALS Study Group
-
Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007, 6:1045-1053. for the Western ALS Study Group.
-
(2007)
Lancet Neurol
, vol.6
, pp. 1045-1053
-
-
Gordon, P.H.1
Moore, D.H.2
Miller, R.G.3
-
24
-
-
70449697216
-
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial
-
Meininger V, Drory V, Leigh P, Ludolph A, Robberecht W, Silani V Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009, 10:378-383.
-
(2009)
Amyotroph Lateral Scler
, vol.10
, pp. 378-383
-
-
Meininger, V.1
Drory, V.2
Leigh, P.3
Ludolph, A.4
Robberecht, W.5
Silani, V.6
-
25
-
-
79952199408
-
Progression in ALS is not linear but is curvilinear
-
Gordon PH, Cheng B, Salachas F, et al. Progression in ALS is not linear but is curvilinear. J Neurol 2010, 257:1713-1717.
-
(2010)
J Neurol
, vol.257
, pp. 1713-1717
-
-
Gordon, P.H.1
Cheng, B.2
Salachas, F.3
-
26
-
-
41149124406
-
Lithium delays progression of amyotrophic lateral sclerosis
-
Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci 2008, 105:2052-2057.
-
(2008)
Proc Natl Acad Sci
, vol.105
, pp. 2052-2057
-
-
Fornai, F.1
Longone, P.2
Cafaro, L.3
-
27
-
-
84859718510
-
Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial
-
Verstraete E, Veldink JH, Huisman MH, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry 2012, 83:557-564.
-
(2012)
J Neurol Neurosurg Psychiatry
, vol.83
, pp. 557-564
-
-
Verstraete, E.1
Veldink, J.H.2
Huisman, M.H.3
-
28
-
-
84875273042
-
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
-
Morrison KE, Dhariwal S, Hornabrook R, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013, 12:339-345.
-
(2013)
Lancet Neurol
, vol.12
, pp. 339-345
-
-
Morrison, K.E.1
Dhariwal, S.2
Hornabrook, R.3
-
29
-
-
77950628380
-
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
-
the Northeast and Canadian Amyotrophic Lateral Sclerosis consortia
-
Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:481-488. the Northeast and Canadian Amyotrophic Lateral Sclerosis consortia.
-
(2010)
Lancet Neurol
, vol.9
, pp. 481-488
-
-
Aggarwal, S.P.1
Zinman, L.2
Simpson, E.3
-
30
-
-
77952168830
-
A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis
-
Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010, 11:266-271.
-
(2010)
Amyotroph Lateral Scler
, vol.11
, pp. 266-271
-
-
Pascuzzi, R.M.1
Shefner, J.2
Chappell, A.S.3
-
31
-
-
79954591299
-
Results of a clinical trial of talampanel in patients with ALS
-
Talampanel ALS Study Group
-
Shefner J, Meininger V Results of a clinical trial of talampanel in patients with ALS. Amyotroph Lateral Scler 2011, 11:44-45. Talampanel ALS Study Group.
-
(2011)
Amyotroph Lateral Scler
, vol.11
, pp. 44-45
-
-
Shefner, J.1
Meininger, V.2
-
32
-
-
84892469426
-
Stage 3 clinical trial of ceftriaxone in subjects with ALS
-
NEALS Consortium, abstr 001.
-
Cudkowicz M, Shefner J Stage 3 clinical trial of ceftriaxone in subjects with ALS. Neurology 2013, 80(suppl 36). NEALS Consortium, abstr 001.
-
(2013)
Neurology
, vol.80
, Issue.SUPPL. 36
-
-
Cudkowicz, M.1
Shefner, J.2
-
33
-
-
53049105819
-
ALS drug development: reflections from the past and a way forward
-
Aggarwal S, Cudkowicz M ALS drug development: reflections from the past and a way forward. Neurotherapeutics 2008, 5:516-527.
-
(2008)
Neurotherapeutics
, vol.5
, pp. 516-527
-
-
Aggarwal, S.1
Cudkowicz, M.2
-
34
-
-
46749128523
-
Designing clinical trials in amyotrophic lateral sclerosis
-
Shefner JM Designing clinical trials in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2008, 19:495-508.
-
(2008)
Phys Med Rehabil Clin N Am
, vol.19
, pp. 495-508
-
-
Shefner, J.M.1
-
35
-
-
77952190999
-
Toward more efficient clinical trials for amyotrophic lateral sclerosis
-
Cudkowicz ME, Katz J, Moore DH, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010, 11:259-265.
-
(2010)
Amyotroph Lateral Scler
, vol.11
, pp. 259-265
-
-
Cudkowicz, M.E.1
Katz, J.2
Moore, D.H.3
-
36
-
-
84876319986
-
Controversies and priorities in amyotrophic lateral sclerosis
-
Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013, 12:310-322.
-
(2013)
Lancet Neurol
, vol.12
, pp. 310-322
-
-
Turner, M.R.1
Hardiman, O.2
Benatar, M.3
|